Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$5.85
-$0.23(-6.52%)
At close: 4:00 PM EST
$5.85
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $8.05
Previous CloseN/A
Volume113.57K
Average Volume (3M)293.34K
Market Cap
$96.14M
Enterprise Value$32.68M
Total Cash (Recent Filing)$50.75M
Total Debt (Recent Filing)$10.99M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Aug 06, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.68
Shares Outstanding16,956,415
10 Day Avg. Volume239,648
30 Day Avg. Volume293,342
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit0.61
Enterprise Value/Ebitda1.48
Forecast
1Y Price Target
$14.33Price Target Upside145.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Reported ProfitabilityThe company’s TTM operating and net margins expanded sharply, delivering high reported profitability on meaningful revenue. Sustained margins increase internal funding capacity for R&D and trials, improve partner negotiation leverage, and lower near-term reliance on dilutive financing if maintained.
Stronger Balance Sheet / Lower LeverageMaterial deleveraging and a meaningful equity base improve financial resilience for a biotech. Lower leverage reduces interest and refinancing pressure, expanding strategic flexibility to fund clinical programs or execute partnerships without immediate distress if operational headwinds recur.
Expanded Equity Funding Capacity (ATM/shelf)A larger at-the-market/shelf capacity meaningfully increases optionality to raise capital over months, smoothing funding for multi-stage clinical programs. This structural funding access reduces the risk of sudden liquidity shortfalls and allows management to time raises strategically.
Bears Say
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow creates a structural financing need for a clinical-stage biotech. Continued cash burn forces regular capital raises, increases dilution risk, and constrains the company's ability to fund expansion or withstand trial delays without external capital.
Flat And Volatile Revenue TrendsFlat recent revenue and a history of volatile top-line results weaken confidence in durability of reported profitability. Without consistent revenue growth, margins may revert, and forecasting becomes harder for investors and partners, raising risk for sustainable self-funding and strategic planning.
Ongoing Dependence On External FinancingRepeated equity programs and ATMs are structural evidence the business cannot yet self-fund development. Reliance on public raises increases dilution potential, ties progress to market access conditions, and exposes programs to funding timing risk if capital markets tighten.
Q32 Bio News
QTTB FAQ
What was Q32 Bio Inc’s price range in the past 12 months?
Q32 Bio Inc lowest stock price was $1.34 and its highest was $8.04 in the past 12 months.
What is Q32 Bio Inc’s market cap?
Q32 Bio Inc’s market cap is $96.14M.
When is Q32 Bio Inc’s upcoming earnings report date?
Q32 Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 76 days.
How were Q32 Bio Inc’s earnings last quarter?
Q32 Bio Inc released its earnings results on May 05, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.14.
Is Q32 Bio Inc overvalued?
According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued.
Does Q32 Bio Inc pay dividends?
Q32 Bio Inc does not currently pay dividends.
What is Q32 Bio Inc’s EPS estimate?
Q32 Bio Inc’s EPS estimate is -0.57.
How many shares outstanding does Q32 Bio Inc have?
Q32 Bio Inc has 16,956,415 shares outstanding.
What happened to Q32 Bio Inc’s price movement after its last earnings report?
Q32 Bio Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Q32 Bio Inc?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (145.01% Upside)
$14.33 (145.01% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $75.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.33%
12-Months-Change
Fundamentals
Return on Equity
230.68%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
QTTB Stock 12 Month Forecast
Average Price Target
$14.33
▲(145.01% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
2.64% Insiders
2.39% Mutual Funds
48.01% Other Institutional Investors
44.52% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---